TWI747816B - 眼用組合物用於製備藥物的用途 - Google Patents

眼用組合物用於製備藥物的用途 Download PDF

Info

Publication number
TWI747816B
TWI747816B TW105106605A TW105106605A TWI747816B TW I747816 B TWI747816 B TW I747816B TW 105106605 A TW105106605 A TW 105106605A TW 105106605 A TW105106605 A TW 105106605A TW I747816 B TWI747816 B TW I747816B
Authority
TW
Taiwan
Prior art keywords
corneal
composition
cornea
dexamethasone
collagen
Prior art date
Application number
TW105106605A
Other languages
English (en)
Chinese (zh)
Other versions
TW201639592A (zh
Inventor
卡洛安 格林
柯林 格林
崔佛 薛爾溫
Original Assignee
紐西蘭商奧克蘭聯合服務有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 紐西蘭商奧克蘭聯合服務有限公司 filed Critical 紐西蘭商奧克蘭聯合服務有限公司
Publication of TW201639592A publication Critical patent/TW201639592A/zh
Application granted granted Critical
Publication of TWI747816B publication Critical patent/TWI747816B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Eyeglasses (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW105106605A 2015-03-05 2016-03-04 眼用組合物用於製備藥物的用途 TWI747816B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ705727 2015-03-05
NZ70572715 2015-03-05

Publications (2)

Publication Number Publication Date
TW201639592A TW201639592A (zh) 2016-11-16
TWI747816B true TWI747816B (zh) 2021-12-01

Family

ID=56848288

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105106605A TWI747816B (zh) 2015-03-05 2016-03-04 眼用組合物用於製備藥物的用途

Country Status (11)

Country Link
US (2) US10842850B2 (https=)
EP (1) EP3265096B9 (https=)
JP (4) JP2018513117A (https=)
KR (1) KR102450674B1 (https=)
CN (1) CN107530360B (https=)
AU (1) AU2016226699B2 (https=)
ES (1) ES2952700T3 (https=)
MY (1) MY186271A (https=)
SG (1) SG11201708114SA (https=)
TW (1) TWI747816B (https=)
WO (1) WO2016140581A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
ES2986057T3 (es) 2012-03-29 2024-11-08 Epion Therapeutics Inc Composiciones y métodos para tratar o prevenir enfermedades asociadas al estrés oxidativo
TWI747816B (zh) 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
KR102706856B1 (ko) 2015-07-21 2024-09-19 아베드로 인코퍼레이티드 광증감제로 눈을 치료하기 위한 시스템 및 방법
CN110092816B (zh) * 2018-01-29 2023-08-01 上海市第一人民医院 预防和治疗纤维化的小分子多肽及其应用
US20210060017A1 (en) * 2018-02-27 2021-03-04 Shilpa Medicare Ltd Methotrexate ophthalmic solution
CN108728418A (zh) * 2018-06-19 2018-11-02 新乡医学院 一种鸡胚中枢神经系统单个神经元动态研究模型的制备方法及应用
WO2020092897A1 (en) * 2018-11-02 2020-05-07 Senseonics, Incorporated Drug eluting matrix on analyte indicator
GB201820021D0 (en) * 2018-12-07 2019-01-23 Univ Birmingham Ocular hydrogel compositions
JP2022125941A (ja) * 2021-02-17 2022-08-29 株式会社ティ・エム・ディ コンタクトレンズ
JP2025529178A (ja) 2022-09-01 2025-09-04 オプティファイ・セラピューティクス・アクティエンゲゼルシャフト 眼科用組成物
EP4687950A1 (en) * 2023-03-30 2026-02-11 Cetel Scientific LLC Amniotic and chorionic collagen for ocular surface healing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032131A1 (en) * 1993-09-29 1996-10-17 Alcon Laboratories, Inc. USE OF TGF-β3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786812A (en) * 1972-03-10 1974-01-22 C Neefe Contact lens for olar drug delivery
US4177268A (en) 1973-05-30 1979-12-04 Jouveinal S.A. Method of alleviating inflammation by administration of dexamethasone derivatives
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
AU660635B2 (en) * 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
CN1770976A (zh) 2003-02-13 2006-05-10 人类起源公司 利用脐带血治疗患有疾病、紊乱或状况的个体的用途
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2007099337A1 (en) 2006-03-01 2007-09-07 Cartela R&D Ab Expansion and differentiation of mesenchymal stem cells
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8110655B2 (en) 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
AU2007319811A1 (en) 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
JP2011505409A (ja) 2007-12-04 2011-02-24 ノバガリ ファーマ エスエー パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
EP2249921B1 (en) 2008-02-25 2020-06-17 Eyegate Pharmaceuticals, Inc. Enhanced delivery of dexamethasone phosphate to ocular tissues through iontophoresis
EP2370054B1 (en) * 2008-12-11 2015-10-07 Massachusetts Institute of Technology Contact lens drug delivery device
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
WO2012088044A2 (en) 2010-12-20 2012-06-28 James Mcmillan Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
KR101518370B1 (ko) 2013-06-25 2015-05-07 가톨릭대학교 산학협력단 Il-10 생성 조절 t세포로의 분화 유도용 조성물
CN104548210A (zh) 2014-12-13 2015-04-29 浙江大学 含地塞米松转化生长因子的可控缓释plga微球及制备
TWI747816B (zh) 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032131A1 (en) * 1993-09-29 1996-10-17 Alcon Laboratories, Inc. USE OF TGF-β3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Carol Greene et al., "Exploring cell plasticity: the corneal keratocyte and beyond", Investigative Ophthalmology & Visual Science, 2013, 54(13)：5250. *
何凱文等, "地塞米松對大鼠角膜酸燒傷療效初探", 國際眼科雜誌, 2014, 14(3)：146-418.
何凱文等, "地塞米松對大鼠角膜酸燒傷療效初探", 國際眼科雜誌, 2014, 14(3)：146-418.; *
郝一豔, "地塞米松在角膜鐵質異物傷術後的應用", 眼外傷職業眼病雜誌, 2010, 32(1)：74-75.
郝一豔, "地塞米松在角膜鐵質異物傷術後的應用", 眼外傷職業眼病雜誌, 2010, 32(1)：74-75.; *

Also Published As

Publication number Publication date
US11938168B2 (en) 2024-03-26
JP2018513117A (ja) 2018-05-24
AU2016226699B2 (en) 2020-10-22
NZ735959A (en) 2021-10-29
CN107530360A (zh) 2018-01-02
US20220047676A1 (en) 2022-02-17
WO2016140581A1 (en) 2016-09-09
MY186271A (en) 2021-07-01
KR20170132197A (ko) 2017-12-01
EP3265096B1 (en) 2023-06-07
JP7641650B2 (ja) 2025-03-07
TW201639592A (zh) 2016-11-16
US10842850B2 (en) 2020-11-24
KR102450674B1 (ko) 2022-10-04
JP2025032318A (ja) 2025-03-11
US20180050088A1 (en) 2018-02-22
ES2952700T3 (es) 2023-11-03
JP2023066425A (ja) 2023-05-15
EP3265096C0 (en) 2023-06-07
JP2021091688A (ja) 2021-06-17
AU2016226699A1 (en) 2017-10-26
EP3265096A1 (en) 2018-01-10
CN107530360B (zh) 2021-09-17
EP3265096A4 (en) 2018-10-24
SG11201708114SA (en) 2017-11-29
EP3265096B9 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
TWI747816B (zh) 眼用組合物用於製備藥物的用途
Liu et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients
Lin et al. Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction
JP2017522016A (ja) 培養哺乳動物輪部幹細胞、その産生方法及びその使用
KR20120102709A (ko) 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
Mertsch et al. The effect of Rho Kinase inhibition on corneal nerve regeneration in vitro and in vivo
CN105555363B (zh) 医药组成物及其用途
You et al. Injectable, antioxidative, and loaded with exosomes/Liproxstatin-1 hydrogel as a potential treatment for retinal ischemia–reperfusion by inhibiting ferroptosis and apoptosis
Jirsova The cornea, anatomy and function
Zhu et al. Ultrasound targeted microbubble destruction promotes the therapeutic effect of HUMSC transplantation on glaucoma-caused optic nerve injury in rabbits
NZ735959B2 (en) Ophthalmic compositions and methods of use therefor
US20160058796A1 (en) Retina extracellular matrix based biomaterial
US20250222035A1 (en) Processes for making and using a mesenchyme stem cell secretome for limbal stem cell deficiency (lscd) treatment
Xu et al. Effects of mesenchymal stem cell exosomes on trabecular meshwork cells via the NRF2 pathway
Shahhossein-Dastjerdi et al. Autophagy and Exocytosis of Lipofuscin Into the Basolateral Extracellular Space of Human Retinal Pigment Epithelium From Fetal Development to Adolescence
Bonzano Cornea to the best of our knowledge
WO2024172043A1 (ja) 網膜色素上皮裂孔の治療薬
WO2025184654A1 (en) Trabecular meshwork cell (tmc) and trabecular meshwork stem cell (tmsc) secretome effects on schlemm's canal endothelial cells (scec)
CN115721656A (zh) 包含瑞巴派特或其盐的药物组合物及其制备方法和在制备眼用制剂中的用途
WO2026043789A1 (en) Targeted delivery of therapeutic cargo to tissues using thermosensitive hydrogels
WO2024054865A2 (en) Preparation and purification methods for mesenchymal stem cell derived secretome
Fronk Methods for Growing Retinal Pigment Epithelial Cells: Current Protocols and Future Recommendations
Chang Analysis of Stem Cells and Wound Healing in the Human Cornea